WO2024027631A1 - 一种稠三环类衍生物的晶型及制备方法 - Google Patents
一种稠三环类衍生物的晶型及制备方法 Download PDFInfo
- Publication number
- WO2024027631A1 WO2024027631A1 PCT/CN2023/110180 CN2023110180W WO2024027631A1 WO 2024027631 A1 WO2024027631 A1 WO 2024027631A1 CN 2023110180 W CN2023110180 W CN 2023110180W WO 2024027631 A1 WO2024027631 A1 WO 2024027631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- compound
- formula
- crystal form
- ether
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 143
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 213
- BHDLTOUYJMTTTM-UHFFFAOYSA-N oxan-3-ol Chemical compound OC1CCCOC1 BHDLTOUYJMTTTM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims description 164
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 108
- 238000003756 stirring Methods 0.000 claims description 88
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 69
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 46
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 21
- 150000002576 ketones Chemical class 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 16
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 16
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 15
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
- -1 3-methyl-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-6-yl Chemical group 0.000 claims description 14
- 239000005453 ketone based solvent Substances 0.000 claims description 14
- 150000002825 nitriles Chemical class 0.000 claims description 11
- 108091007914 CDKs Proteins 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 9
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 239000004210 ether based solvent Substances 0.000 claims description 7
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000005456 alcohol based solvent Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003759 ester based solvent Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 229940049920 malate Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LYGJENNIWJXYER-BJUDXGSMSA-N nitromethane Chemical group [11CH3][N+]([O-])=O LYGJENNIWJXYER-BJUDXGSMSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 description 68
- 238000001514 detection method Methods 0.000 description 52
- 239000000047 product Substances 0.000 description 49
- 238000001228 spectrum Methods 0.000 description 35
- 239000000243 solution Substances 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 22
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- 239000012065 filter cake Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000004949 mass spectrometry Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000011521 glass Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 6
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 3
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GMHKMTDVRCWUDX-LBPRGKRZSA-N (S)-Mephenytoin Chemical compound C=1C=CC=CC=1[C@]1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-LBPRGKRZSA-N 0.000 description 2
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- KJBONRGCLLBWCJ-UHFFFAOYSA-N 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol;hydron;chloride Chemical compound Cl.CCC1=CC=CC2=C1OC(C(O)CNC(C)(C)C)=C2 KJBONRGCLLBWCJ-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- VHHPDZDTKZOHTB-UHFFFAOYSA-M [Br-].[Mg+]C.C1CCOC1 Chemical compound [Br-].[Mg+]C.C1CCOC1 VHHPDZDTKZOHTB-UHFFFAOYSA-M 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- QJWQYOHBMUQHGZ-UHFFFAOYSA-N ethanol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CCO.OC(=O)CC(O)(C(O)=O)CC(O)=O QJWQYOHBMUQHGZ-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004441 surface measurement Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- PBQHDTRHGNGTLZ-RFZPGFLSSA-N (3s,4r)-4-aminooxan-3-ol Chemical compound N[C@@H]1CCOC[C@H]1O PBQHDTRHGNGTLZ-RFZPGFLSSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKBWHRMIYKMDDN-UHFFFAOYSA-N 2-methyl-1-propoxypropane Chemical group CCCOCC(C)C NKBWHRMIYKMDDN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 101100481028 Arabidopsis thaliana TGA2 gene Proteins 0.000 description 1
- GBEZFWMDMFCQJJ-UHFFFAOYSA-N CC(COC1=C(C=C2F)Br)N3C1=C2N=C3C(C)(C)O Chemical compound CC(COC1=C(C=C2F)Br)N3C1=C2N=C3C(C)(C)O GBEZFWMDMFCQJJ-UHFFFAOYSA-N 0.000 description 1
- HFNAWRSJFJKZGR-UHFFFAOYSA-N CC(COC1=C(C=C2F)Br)N3C1=C2N=C3C=O Chemical compound CC(COC1=C(C=C2F)Br)N3C1=C2N=C3C=O HFNAWRSJFJKZGR-UHFFFAOYSA-N 0.000 description 1
- ZUNGGJHBMLMRFJ-UHFFFAOYSA-N CCOP(=O)=O Chemical compound CCOP(=O)=O ZUNGGJHBMLMRFJ-UHFFFAOYSA-N 0.000 description 1
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100187477 Homo sapiens NR1I2 gene Proteins 0.000 description 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HUXYBQXJVXOMKX-UHFFFAOYSA-N N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide Chemical compound CC(C)CC(=O)NC1=NNC(C2(C)C)=C1CN2C(=O)C1CCN(C)CC1 HUXYBQXJVXOMKX-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 101100361293 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rpn12 gene Proteins 0.000 description 1
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- UTPHCDAXLJPLCD-UHFFFAOYSA-N ethanol;methanesulfonic acid Chemical compound CCO.CS(O)(=O)=O UTPHCDAXLJPLCD-UHFFFAOYSA-N 0.000 description 1
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000056262 human PPIG Human genes 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Definitions
- the present disclosure relates to a crystal form of a fused tricyclic derivative and a preparation method, and belongs to the field of pharmaceuticals.
- Cyclin-dependent kinases are important cellular enzymes that play an important role in regulating eukaryotic cell division and proliferation.
- the cyclin-dependent kinase catalytic unit is activated by regulatory subunits called cyclins. At least 16 mammalian cell cyclins have been identified (Annu. Rev. Pharmacol. Toxicol. (1999) 39:295-312).
- Cyclin B/CDK1, cyclin A/CDK2, cyclin E/CDK2, cyclin D/CDK4, cyclin D/CDK6 and possibly other heterodynes are important regulators of cell cycle progression.
- Other functions of cyclin/CDK heterodynes include transcriptional regulation, DNA repair, differentiation and apoptosis (Annu. Rev. Cell. Dev. Biol. (1997) 13: 261-291).
- PCT/CN2022/074509 provides a new class of cyclin-dependent kinase inhibitors. Finding the development forms of the compounds disclosed in this application has important clinical significance.
- the present disclosure provides compound (3S,4R)-4-((5-chloro-4-((S)-8-fluoro-2-(2-hydroxypropan-2-yl)-3-methyl-3,4 -Dihydro-5-oxa-1,2a-acenaphthylene-6-yl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (compound represented by formula (I) ), its pharmaceutically acceptable salts, and corresponding preparation methods,
- the present disclosure provides a crystal form A of the compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 9.6, 10.0, 11.7, 15.0, 21.1, and 21.7.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the A crystal form of the compound represented by formula (I) provided by the present disclosure is 7.8, 9.6, 10.0, 11.7, 15.0, 18.9, 19.4 There are characteristic peaks at , 20.1, 21.1, and 21.7.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the A crystal form of the compound represented by formula (I) provided by the present disclosure is at 7.8, 9.6, 10.0, 11.7, 15.0, 18.9, There are characteristic peaks at 19.4, 20.1, 21.1, 21.7, 23.5, 26.7, and 29.4.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the crystal form A of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 2.
- the present disclosure provides a method for preparing crystal form A of the compound represented by formula (I), which includes the following steps:
- the solvent 1 is selected from ketone solvents or ester solvents, and the solvent 2 is an ether solvent.
- the ketone solvent is selected from acetone or methyl isobutyl ketone
- the ester solvent is ethyl acetate
- the ether solvent is selected from isopropyl ether or methyl tert-butyl ketone. base ether.
- the compound represented by formula (I) is dissolved in solvent 3, stirred and crystallized.
- the solvent 3 is selected from ester solvents and ketone solvents; preferably, the ester solvent is selected from ethyl acetate, isopropyl acetate ester, and the ketone solvent is methyl isobutyl ketone.
- the present disclosure provides a B crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 11.3, 15.1, 20.9, 22.8, and 23.7.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the B crystal form of the compound represented by formula (I) provided by the present disclosure is at 7.4, 11.3, 14.3, 15.1, 16.3, 18.0, There are characteristic peaks at 20.0, 20.9, 22.8, 23.2, 23.7, 25.1, and 26.0.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the B crystal form of the compound represented by formula (I) provided by the present disclosure is at 7.4, 9.5, 11.3, 12.4, 12.8, 13.7, There are characteristic peaks at 14.3, 15.1, 16.3, 18.0, 19.2, 20.0, 20.9, 22.8, 23.2, 23.7, 25.1, 26.0, 26.8, 28.2, 30.4, 32.7, 33.6, 34.3, 35.5, 38.4, 39.0, 40.5.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the B crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 3.
- the present disclosure provides a method for preparing the B crystal form of a compound represented by formula (I), which includes the following steps: dissolving the compound represented by formula (I) in a substituted lower alkane, and stirring to crystallize.
- the substituted lower alkane is nitromethane.
- the present disclosure provides a C crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 4.8, 10.1, 12.0, and 15.0.
- the C crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ at 4.8, 7.6, 10.1, 12.0, 15.0, 19.7, There are characteristic peaks at 21.2 and 23.5.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the C crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 4.
- the present disclosure provides a method for preparing the C crystal form of the compound represented by formula (I), which is selected from the following methods:
- the solvent 4 is selected from substituted lower alkanes or ketone solvents; optionally, the substituted lower alkane is selected from dichloromethane or 1,2 -Dichloroethane, the ketone solvent is methyl isobutyl ketone;
- solvent 5 Dissolve the compound represented by formula (I) in solvent 5, stir and crystallize, and the solvent 5 is selected from aromatic hydrocarbon solvents; optionally, the aromatic hydrocarbon solvent is selected from p-xylene or toluene;
- the solvent 6 is selected from alcoholic solvents, ketone solvents, nitrile solvents, and ether solvents, and the solvent 7 is an ether solvent; optionally, the alcoholic solvent is selected from isopropanol or ethanol, and the The ketone solvent is acetone, the nitrile solvent is acetonitrile, and the ether solvent is selected from tetrahydrofuran or isopropyl ether.
- the present disclosure provides a D crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 10.0, 10.5, 17.0, 18.7, and 23.9.
- the D crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ , at 10.0, 10.5, 11.0, 13.4, 15.9, 17.0, There are characteristic peaks at 18.3, 18.7, 20.8, 23.9, and 28.0.
- the D crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ at 10.0, 10.5, 11.0, 12.5, 13.4, 15.9, There are characteristic peaks at 17.0, 18.3, 18.7, 20.1, 20.8, 22.3, 23.9, 26.7, 28.0, 30.5, 31.0, 32.1, 33.1, 33.8, and 34.6.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the D crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 5.
- the present disclosure provides a method for preparing the D crystal form of the compound represented by formula (I), which includes the following steps: mixing the compound represented by formula (I) with solvent 8, stirring for crystallization, and the solvent 8 is an ether solvent, Or a mixed solvent of alcohol solvent and ether solvent; optionally, the alcohol solvent is methanol, ethanol or isopropyl alcohol, and the ether solvent is isopropyl ether.
- the present disclosure provides an E crystal form of the compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 4.8, 11.4, 14.4, 15.1, 16.4, 19.3, and 22.9.
- the E crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ , at 4.8, 7.4, 11.4, 14.4, 15.1, 16.4, There are characteristic peaks at 17.9, 19.3, 19.9, 20.9, 22.9, and 23.5.
- the E crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ at 4.8, 7.4, 9.6, 11.4, 14.4, 15.1, There are characteristic peaks at 16.4, 17.9, 19.3, 19.9, 20.9, 22.9, 23.5, 24.2, 25.2, 25.9, 26.8, and 30.5.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the E crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 6.
- the present disclosure provides a method for preparing the E crystal form of the compound represented by the Chinese formula (I), which is selected from the following methods:
- the solvent 9 is a nitrile solvent, optionally, the nitrile solvent is acetonitrile;
- the solvent 10 is selected from ketone solvents, and the solvent 11 is an ether solvent; optionally, the ketone solvent is acetone, and the ether solvent is isopropyl ether.
- the present disclosure provides an F crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 11.1, 11.4, 14.3, 15.1, 15.7, 19.2, and 22.0.
- the F crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ , at 9.1, 11.1, 11.4, 13.3, 14.3, 15.1, There are characteristic peaks at 15.7, 16.6, 17.9, 19.2, 20.0, 21.1, 22.0, 23.6, 24.6, and 26.1.
- the F crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ at 4.8, 9.1, 9.8, 11.1, 11.4, 12.0, There are characteristic peaks at 13.3, 14.3, 15.1, 15.7, 16.6, 17.9, 19.2, 20.0, 21.1, 22.0, 22.5, 23.6, 24.2, 24.6, 25.2, 25.6, 26.1, 28.7, 30.3, and 35.0.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the F crystal form of the compound represented by formula (I) provided by the present disclosure is shown in Figure 7 .
- the present disclosure provides a method for preparing the F crystal form of the compound represented by formula (I), which is selected from the following methods:
- the compound represented by formula (I) is dissolved in solvent 12, stirred and crystallized.
- the solvent 12 is a ketone solvent; optionally, the ketone solvent is methyl isobutyl ketone;
- the present disclosure provides a G crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 11.3, 15.3, 16.1, 17.9, 18.6, and 20.8.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the G crystal form of the compound represented by formula (I) provided by the present disclosure is at 11.3, 15.3, 16.1, 17.9, 18.6, 20.8, There are characteristic peaks at 22.8, 23.1, 23.8, and 25.8.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the G crystal form of the compound represented by formula (I) provided by the present disclosure is at 9.1, 11.3, 12.6, 13.8, 14.7, 15.3, There are characteristic peaks at 16.1, 17.0, 17.5, 17.9, 18.6, 19.6, 20.8, 21.6, 22.8, 23.1, 23.8, 24.3, 25.3, 25.8, 27.3, 27.8, 29.3, 30.8, 32.3, 33.6, 34.5, 35.0.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the G crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 8.
- the present disclosure provides a method for preparing the G crystal form of the compound represented by formula (I), which includes the following steps: dissolving the compound represented by formula (I) in a mixed solvent of alcohol solvent and ether solvent, stirring and crystallizing;
- the alcohol solvent is selected from methanol
- the ether solvent is isopropyl ether.
- the present disclosure provides an H crystal form of a compound represented by formula (I).
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ has characteristic peaks at 11.7, 12.3, 15.5, 19.4, and 22.3.
- the H crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ , at 11.7, 12.3, 15.5, 18.2, 19.4, 21.3, There are characteristic peaks at 22.3, 24.9, 27.1, and 28.1.
- the H crystal form of the compound represented by formula (I) provided by the present disclosure has an X-ray powder diffraction pattern expressed as a diffraction angle 2 ⁇ , at 10.1, 11.7, 12.3, 12.8, 13.4, 15.5, There are characteristic peaks at 17.1, 18.2, 19.4, 20.5, 21.3, 22.3, 23.2, 24.5, 24.9, 25.6, 26.4, 27.1, 28.1, 28.4, 30.7, 31.2, 32.1, 33.3, 36.0, 37.0, and 39.2.
- the X-ray powder diffraction pattern expressed by the diffraction angle 2 ⁇ of the H crystal form of the compound represented by formula (I) provided by the present disclosure is as shown in Figure 9.
- the present disclosure provides a method for preparing the H crystal form of the compound represented by formula (I), which is selected from the following methods:
- the solvent 13 is selected from alcohol solvents, mixed solvents of alcohol solvents and water, ketone solvents or ester solvents; optionally, The alcohol solvent is selected from methanol, ethanol, isopropanol, and n-propanol, the ketone solvent is selected from acetone, 2-butanone, and methyl isobutyl ketone, and the ester solvent is ethyl acetate;
- the compound represented by formula (I) is mixed with a solvent 14, beaten and crystallized.
- the solvent 14 is selected from water or an ether solvent; optionally, the ether solvent is selected from methyl tert-butyl ether or isopropyl ether. ;
- the solvent 15 is selected from alcohol solvents, ketone solvents, and ether solvents
- the solvent 16 is selected from lower alkanes, ether solvents or water; optionally, the alcohol solvent is selected from isopropanol, so
- the ketone solvent is acetone
- the lower alkane is n-heptane
- the ether solvent is tetrahydrofuran, isopropyl ether or methyl tert-butyl ether.
- Another aspect of the present disclosure provides a pharmaceutically acceptable salt of the compound represented by formula (I).
- the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, sulfate, methanesulfonate, p-toluenesulfonate, and phosphate. , citrate or malate.
- the ratio of the compound represented by formula (I) to the acid molecule is selected from about 3:1-1:3, specifically about 1:1, 1:2 or 1:3.
- the present disclosure provides a method for preparing a pharmaceutically acceptable salt of a compound represented by formula (I), which includes the step of reacting a free base with an acid molecule.
- the acid molecule is selected from hydrochloric acid, sulfuric acid, methanesulfonic acid, and p-toluenesulfonic acid. , phosphoric acid, citric acid or malic acid.
- the present disclosure provides a method for preparing a pharmaceutically acceptable salt of the compound represented by formula (I), in which the reaction occurs under the action of a solvent.
- the solvent is a nitrile solvent, an alcohol solvent, an ester solvent, an aromatic hydrocarbon solvent, an ether solvent, a ketone solvent, or a substituted lower alkane solvent.
- the nitrile solvent is acetonitrile.
- the alcoholic solvent is ethanol.
- the pharmaceutically acceptable salts of the compounds represented by formula (I) provided by the present disclosure can be in any crystalline form or amorphous form.
- the substituted lower alkane described in this disclosure can be selected from nitromethane, dichloromethane, and chloroform;
- the nitrile solvent is selected from acetonitrile or propionitrile;
- the alcohol solvent refers to C 1 -C 6 Alcohol, optional methanol, ethanol, n-propanol, isopropanol, n-butanol;
- the ketone solvent is selected from acetone, 2-butanone, methyl isobutyl ketone;
- the ether solvent is selected from isobutanol Propyl ether, tetrahydrofuran, dioxane, propylene glycol methyl ether;
- the ester solvent is selected from ethyl acetate, methyl acetate, isopropyl acetate;
- the lower alkane is selected from n-hexane or n-heptane.
- the ratio of the solvent can be 0.1-100 times (w/v) of the compound represented by formula (I), specifically, it can be 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or any value in between.
- the preparation method of the crystal form provided by the present disclosure includes the step of separating solid and liquid, which may be filtration, centrifugation or complete evaporation of the solvent.
- the preparation method of the crystalline form provided by the present disclosure may optionally include a drying step.
- the present disclosure also provides a pharmaceutical composition, which contains any of the aforementioned crystal forms or pharmaceutically acceptable salts, or mixtures thereof, and pharmaceutical excipients optionally selected from pharmaceutically acceptable excipients.
- the present disclosure also provides a method for preparing a pharmaceutical composition, which includes the step of mixing any of the aforementioned crystal forms or pharmaceutically acceptable salts with pharmaceutically acceptable excipients.
- the present disclosure also provides any of the foregoing crystal forms or pharmaceutically acceptable salts, or the foregoing compositions in preparation for treatment or Use in drugs to prevent diseases associated with cyclin-dependent kinases.
- the present disclosure also provides the use of any of the foregoing crystal forms or pharmaceutically acceptable salts, or the foregoing compositions in the preparation of medicaments for the treatment or prevention of cancer.
- the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, intestinal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer and thyroid cancer. cancer.
- the "2 ⁇ or 2 ⁇ angle" mentioned in this disclosure refers to the diffraction angle, ⁇ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2 ⁇ is ⁇ 0.2 (including numbers exceeding 1 decimal place after rounding case), can be -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, -0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17 ,0.18,0.19,0.20.
- the drying temperature mentioned in this disclosure is generally 25°C to 100°C, preferably 40°C to 70°C. Drying can be done under normal pressure or under reduced pressure, and the pressure is ⁇ -0.08MPa.
- Excipients include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent that has been approved by the U.S. Food and Drug Administration as acceptable for use in humans or livestock animals. , preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents or emulsifiers.
- the "beating” mentioned in this disclosure refers to a method of purification that utilizes the characteristics of a substance that has poor solubility in a solvent but good impurity solubility in the solvent. Beating and purification can remove color, change the crystal form, or remove a small amount of impurities.
- the starting materials used in the crystal form preparation method of the present disclosure can be compounds in any form. Specific forms include but are not limited to: amorphous, any crystal form, hydrate, solvate, etc.
- the ratio of the compound represented by formula (I) to acid in the present disclosure is within a reasonable error range of ⁇ 10%. It can be ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2% or ⁇ 1%.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS). NMR shifts ( ⁇ ) are given in units of 10 -6 (ppm). NMR was measured using a Bruker AVANCE NEO 500M nuclear magnetic instrument. The measurement solvents were deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), and deuterated methanol (CD 3 OD). The internal standard was tetrahydrofuran. Methylsilane (TMS).
- MS was measured using Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS).
- HPLC High-performance liquid chromatography
- Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
- High-performance liquid phase preparation uses Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs.
- Chiral preparation uses Shimadzu LC-20AP preparative chromatograph.
- CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
- Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates.
- the specifications of silica gel plates used in thin layer chromatography (TLC) are 0.15mm ⁇ 0.2mm.
- the specifications used for thin layer chromatography separation and purification products are 0.4mm. ⁇ 0.5mm.
- Silica gel column chromatography generally uses Yantai Huanghai Silica Gel 200 ⁇ 300 mesh silica gel as the carrier.
- the average kinase inhibition rate and IC 50 value were measured using NovoStar microplate reader (BMG Company, Germany).
- the known starting materials of the present disclosure can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui Chemical companies.
- Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1L.
- the hydrogen atmosphere refers to the reaction bottle connected to a hydrogen balloon with a volume of about 1L.
- the pressurized hydrogenation reaction uses Parr 3916EKX hydrogenator and Clear Blue QL-500 hydrogen generator or HC2-SS hydrogenator.
- the hydrogenation reaction is usually evacuated, filled with hydrogen, and repeated three times.
- the microwave reaction uses CEM Discover-S 908860 microwave reactor.
- the solution refers to an aqueous solution.
- the reaction temperature is room temperature, which is 20°C to 30°C.
- the reaction progress in the embodiment is monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the developing agent used in the reaction, the column chromatography eluent system and the thin layer chromatography developing agent system used to purify the compound include: A: In the methylene chloride/methanol system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
- DVS dynamic moisture adsorption
- the test uses Surface Measurement Systems advantage 2. At 25°C, the humidity ranges from 50%-95%-0%-95%-50%RH in steps of 10%. The judgment standard is that the quality change of each gradient dM/dT is less than 0.002%. , TMAX 360min, cycle twice.
- Example 50 Stability study of factors affecting crystal form
- the sampling inspection period is 30 days. .
- the free sample was sealed in an aluminum foil bag and placed under 25°C/60%RH and 40°C/75%RH conditions to examine the stability.
- the results are as follows.
- Crystal Form H has good physical and chemical stability after being placed under long-term accelerated conditions for 3 months.
- Crystal Form D, Form E, Form F, and Form G have good physical and chemical stability after being placed under long-term accelerated conditions for 6 months.
- the free amorphous form accelerates deliquescence and has good physical and chemical stability under other conditions.
- 6-bromo-8-fluoro-3-methyl-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-2-carbaldehyde 930 mg, 3.1 mmol
- 20mL tetrahydrofuran Cool the temperature to -20°C, add methylmagnesium bromide tetrahydrofuran solution (3mol/L, 1.5ml, 4.5mmol) dropwise, and react at -20°C for 4 hours. 5 ml of water was added to quench the reaction, and the reaction solution was concentrated under reduced pressure. The residue was purified by C-18 reverse-phase chromatography to obtain the title compound 4b (830 mg, yield: 85%).
- reaction solution was cooled to room temperature, and 1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphoryladamantane (58 mg, 0.2 mmol), potassium carbonate ( 221mg, 1.6mmol), 2,4-dichloro-5-fluoropyrimidine (220mg, 1.2mmol), tris(dibenzylideneacetone)dipalladium (183mg, 0.2mmol) and 1mL water, reaction 1 at 80°C Hour.
- the reaction solution was cooled to room temperature, filtered, and the filtrate was collected, concentrated under reduced pressure, and the residue was purified by C-18 reverse-phase chromatography to obtain the title compound 4e (129 mg, yield: 41%).
- Mobile phase A: CO 2 B: ethanol (0.05% DEA), Gradient: from 5% to 40% of B in 2min and hold 40% for 1.2min, then 5% of B for 0.8min;
- Compound A is example A94 of WO 2019/207463A1, which was synthesized by referring to the method disclosed in this patent.
- CDK2, CDK9 The starting concentration of in vitro CDK (CDK2, CDK9) kinase activity test is 1uM, diluted 3 times, a total of 10 concentrations, tested in duplicate.
- Compound PHA-793887 was used as a control compound.
- Use 1x kinase reaction buffer to prepare 2x enzyme (0.3ng/uL CDK2/CyclinE1 or CDK9/CyclinT1), add 2.5uL of the above kinase solution to each well, seal the reaction plate with a sealing plate, centrifuge at 1000g for 1 minute, and leave it at room temperature for 10 minutes .
- the 2 ⁇ CDK2/CylinE1 kinase substrate is 0.4 mg/ml Histone H1 and 30 ⁇ M ATP. Add 2.5 ⁇ L of 2 ⁇ Histone H1 and ATP mixture to the reaction plate, centrifuge at 1000g for 30 seconds to start the reaction.
- %inhibition 100-(Signalcmpd-SignalAve_PC)/(SignalAve_VC-SignalAve_PC) ⁇ 100.
- SignalAve_PC The average value of all positive control wells in the entire plate.
- SignalAve_VC The average value of all negative control wells in the entire plate.
- CDK CDK1, CDK4, CDK6, CDK9 kinase biochemical inhibitory activity of the disclosed compounds was measured through the above test.
- the measured IC 50 values are shown in Table 17 and Table 18.
- CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 were used to evaluate the metabolic responses of representative substrates of the five major human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
- Liquid chromatography tandem mass spectrometry (LC/MS/MS) was used to determine the response of test compounds at different concentrations to phenacetin (CYP1A2), diclofenac sodium (CYP2C9), S-mephenytoin (CYP2C19), and bufuralol hydrochloride. Effects of salt (CYP2D6) and midazolam (CYP3A4/5) metabolic reactions.
- Peak area ratio metabolite peak area/internal standard peak area
- Residual activity ratio (%) peak area ratio of the compound group to be tested/peak area ratio of the blank group
- CYP half inhibitory concentration (IC 50 ) was calculated by Excel XLfit 5.3.1.3.
- thermodynamic solubility of compounds in phosphate buffer, pH 7.4, was determined. Sample supernatants and standards of known concentration were measured by LC/MS/MS.
- Compound A is example A94 of WO 2019/207463A1, synthesized by referring to the method disclosed in this patent.
- NaH 2 PO 4 ⁇ 2H 2 O analytical grade
- NaH 2 PO 4 analytical grade
- NaOH analytical grade
- test compound Evaluate the potential of the test compound to induce the activity of drug metabolizing enzymes by activating PXR in vitro.
- the test compound was measured by in vitro activation of PXR at different concentrations of the test compound (30, 10, 3.33, 1.11, 0.370 and 0.123 ⁇ M) to obtain the EC50 value.
- concentrations of positive control rifampicin were 20, 5, 1.25, 0.312, 0.0781 and 0.195 ⁇ M.
- DPX2 human PXR gene and fluorescent reporter gene stably transfected into HepG2 cells
- the client provides the compound to be tested, and the control drug (rifampicin) is purchased from Sigma (St. Louis, MO).
- CellTiter-Fluor TM cell viability detection kit and One-Glo fluorescence detection kit were purchased from Promega (Madison, WI), fetal bovine serum (FBS) was purchased from Corning (Manassas, VA), and MTS3 oscillator was purchased from IKA Labortechnik (Staufen, Germany), DMEM, penicillin and streptomycin were purchased from local supplier HygromycinB and G418 were purchased from Merck (Darmstadt, Germany), cell culture medium and DPX2 cells were purchased from Puracyp Inc.
- FBS fetal bovine serum
- MTS3 oscillator was purchased from IKA Labortechnik (Staufen, Germany)
- DMEM penicillin and streptomycin were purchased from local supplier HygromycinB and G418 were purchased from Merck (Darmstadt, Germany)
- cell culture medium and DPX2 cells were purchased from Puracyp Inc.
- DPX2 cells were cultured in a T-75 culture bottle in an incubator at 37°C, 5% CO2, and 95% relative humidity. The cells were digested when the cells covered 80-90% of the bottom of the culture bottle.
- test compounds and positive compounds (rifampicin) with DMSO and dilute the compounds with serum-free medium at 37°C.
- the final concentrations of positive control rifampicin were 20, 5, 1.25, 0.312, 0.0781, and 0.195 ⁇ M, and the final concentrations of the test compounds were 30, 10, 3.33, 1.11, 0.370, and 0.123 ⁇ M.
- the final concentration of DMSO is 0.1%. Add 1 ⁇ L of DMSO to the medium containing 1 mL of pre-incubation as a solvent control group.
- I is the fluorescence intensity of the sample
- I (vehicle) refers to the fluorescence intensity of cells with 0.1% DMSO.
- RFU/RLU The activity of luciferase is reflected by RFU/RLU.
- RLU is the average luminescence intensity value of two parallels for each concentration of each compound.
- RFU is the average fluorescence intensity of two parallels for each concentration of each compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
本公开涉及一种稠三环类衍生物的晶型及制备方法。具体而言,涉及化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的晶型、其可药用盐,以及对应的制备方法。
Description
本申请要求申请日为2022/8/1的中国专利申请202210915848.1的优先权。本申请引用上述中国专利申请的全文。
本公开涉及一种稠三环类衍生物的晶型及制备方法,属于制药领域。
细胞周期蛋白-依赖性激酶(CDK)是重要的细胞酶,其在调节真核细胞分裂和增殖中发挥重要作用。细胞周期蛋白-依赖性激酶催化单元被称为细胞周期蛋白的调节亚基激活。已经鉴定出至少16种哺乳动物细胞周期蛋白(Annu.Rev.Pharmacol.Toxicol.(1999)39:295-312)。细胞周期蛋白B/CDK1、细胞周期蛋白A/CDK2、细胞周期蛋白E/CDK2、细胞周期蛋白D/CDK4、细胞周期蛋白D/CDK6和可能的其他heterodynes是细胞周期进展的重要调节因子。细胞周期蛋白/CDK heterodynes的其他功能包括转录调节、DNA修复、分化和凋亡(Annu.Rev.Cell.Dev.Biol.(1997)13:261-291)。
PCT/CN2022/074509提供了一类新的细胞周期蛋白-依赖性激酶抑制剂,寻找该申请中公开化合物的开发形式,具有重要的临床方面的意义。
发明内容
本公开提供化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇(式(I)所示化合物)的晶型、其可药用盐,以及对应的制备方法,
本公开提供一种式(I)所示化合物的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在9.6、10.0、11.7、15.0、21.1、21.7处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,7.8、9.6、10.0、11.7、15.0、18.9、19.4、20.1、21.1、21.7处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在7.8、9.6、10.0、11.7、15.0、18.9、19.4、20.1、21.1、21.7、23.5、26.7、29.4处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图2所示。
本公开提供一种式(I)所示化合物的A晶型的制备方法,包含以下步骤:
方法一
a)将式(I)所示化合物溶于溶剂1;
b)加入溶剂2,析出晶体;
所述溶剂1选自酮类溶剂或酯类溶剂,所述的溶剂2为醚类溶剂。
可选的实施方案中,所述酮类溶剂选自丙酮或甲基异丁基酮,所述的酯类溶剂为乙酸乙酯,所述的醚类溶剂选自异丙醚或甲基叔丁基醚。
方法二
将式(I)所示化合物溶于溶剂3,搅拌析晶,所述的溶剂3选自酯类溶剂和酮类溶剂;优选地,所述的酯类溶剂选自乙酸乙酯、乙酸异丙酯,所述酮类溶剂为甲基异丁基酮。
本公开提供一种式(I)所示化合物的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.3、15.1、20.9、22.8、23.7处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在7.4、11.3、14.3、15.1、16.3、18.0、20.0、20.9、22.8、23.2、23.7、25.1、26.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在7.4、9.5、11.3、12.4、12.8、13.7、14.3、15.1、16.3、18.0、19.2、20.0、20.9、22.8、23.2、23.7、25.1、26.0、26.8、28.2、30.4、32.7、33.6、34.3、35.5、38.4、39.0、40.5处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图3所示。
本公开提供一种式(I)所示化合物的B晶型的制备方法,包括以下步骤:将式(I)所示化合物溶于取代的低级烷烃,搅拌析晶。
可选的实施方案中,所述的取代的低级烷烃为硝基甲烷。
本公开提供一种式(I)所示化合物的C晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、10.1、12.0、15.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的C晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、7.6、10.1、12.0、15.0、19.7、21.2、23.5处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的C晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图4所示。
本公开提供一种式(I)所示化合物的C晶型的制备方法,选自以下方法:
方法一
将式(I)所示化合物溶于溶剂4,挥发析晶,所述溶剂4选自取代低级烷烃或酮类溶剂;可选地,所述的取代低级烷烃选自二氯甲烷或1,2-二氯乙烷,所述的酮类溶剂为甲基异丁基酮;
方法二
将式(I)所示化合物溶于溶剂5,搅拌析晶,所述的溶剂5选自芳香烃类溶剂;可选地,所述的芳香烃类溶剂选自对二甲苯或甲苯;
方法三
a)将式(I)所示化合物溶于溶剂6;
b)加入溶剂7,析出晶体;
所述溶剂6选自醇类溶剂、酮类溶剂、腈类溶剂、醚类溶剂,所述溶剂7为醚类溶剂;可选地,所述醇类溶剂选自异丙醇或乙醇,所述酮类溶剂为丙酮,所述腈类溶剂为乙腈,所述醚类溶剂选自四氢呋喃或异丙醚。
本公开提供一种式(I)所示化合物的D晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在10.0、10.5、17.0、18.7、23.9处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的D晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在10.0、10.5、11.0、13.4、15.9、17.0、18.3、18.7、20.8、23.9、28.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的D晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在10.0、10.5、11.0、12.5、13.4、15.9、17.0、18.3、18.7、20.1、20.8、22.3、23.9、26.7、28.0、30.5、31.0、32.1、33.1、33.8、34.6处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的D晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图5所示。
本公开提供一种式(I)所示化合物的D晶型的制备方法,包括以下步骤:将式(I)所示化合物与溶剂8混合,搅拌析晶,所述溶剂8为醚类溶剂,或醇类溶剂与醚类溶剂的混合溶剂;可选地,所述的醇类溶剂为甲醇、乙醇或异丙醇,所述醚类溶剂为异丙醚。
本公开提供一种式(I)所示化合物的E晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、11.4、14.4、15.1、16.4、19.3、22.9处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的E晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、7.4、11.4、14.4、15.1、16.4、17.9、19.3、19.9、20.9、22.9、23.5处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的E晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、7.4、9.6、11.4、14.4、15.1、16.4、17.9、19.3、19.9、20.9、22.9、23.5、24.2、25.2、25.9、26.8、30.5处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的E晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图6所示。
本公开提供中式(I)所示化合物的E晶型的制备方法,选自以下方法:
方法一
将式(I)所示化合物溶于溶剂9,搅拌析晶,所述溶剂9为腈类溶剂,可选地,所述的腈类溶剂为乙腈;
方法二
a)将式(I)所示化合物溶于溶剂10,
b)加入溶剂11,析出晶体;
所述的溶剂10选自酮类溶剂,所述的溶剂11为醚类溶剂;可选地,所述的酮类溶剂为丙酮,所述的醚类溶剂为异丙醚。
本公开提供一种式(I)所示化合物的F晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.1、11.4、14.3、15.1、15.7、19.2、22.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的F晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在9.1、11.1、11.4、13.3、14.3、15.1、15.7、16.6、17.9、19.2、20.0、21.1、22.0、23.6、24.6、26.1处有特征峰.
可选的实施方案中,本公开提供的式(I)所示化合物的F晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、9.1、9.8、11.1、11.4、12.0、13.3、14.3、15.1、15.7、16.6、17.9、19.2、20.0、21.1、22.0、22.5、23.6、24.2、24.6、25.2、25.6、26.1、28.7、30.3、35.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的F晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图7所示。
本公开提供一种式(I)所示化合物的F晶型的制备方法,选自以下方法:
方法一
将式(I)所示化合物溶于溶剂12,搅拌析晶,所述溶剂12为酮类溶剂;可选地,所述的酮类溶剂为甲基异丁基酮;
方法二
将式(I)所示化合物溶于四氢呋喃,溶清,加入异丙醚和F晶型的晶种,析出晶体。
本公开提供一种式(I)所示化合物的G晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.3、15.3、16.1、17.9、18.6、20.8处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的G晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.3、15.3、16.1、17.9、18.6、20.8、22.8、23.1、23.8、25.8处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的G晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在9.1、11.3、12.6、13.8、14.7、15.3、16.1、17.0、17.5、17.9、18.6、19.6、20.8、21.6、22.8、23.1、23.8、24.3、25.3、25.8、27.3、27.8、29.3、30.8、32.3、33.6、34.5、35.0处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的G晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图8所示。
本公开提供一种式(I)所示化合物的G晶型的制备方法,包括以下步骤:将式(I)所示化合物溶于醇类溶剂和醚类溶剂的混合溶剂,搅拌析晶;可选地,所述醇类溶剂选自甲醇,所述醚类溶剂为异丙醚。
本公开提供一种式(I)所示化合物的H晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.7、12.3、15.5、19.4、22.3处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的H晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.7、12.3、15.5、18.2、19.4、21.3、22.3、24.9、27.1、28.1处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的H晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在10.1、11.7、12.3、12.8、13.4、15.5、17.1、18.2、19.4、20.5、21.3、22.3、23.2、24.5、24.9、25.6、26.4、27.1、28.1、28.4、30.7、31.2、32.1、33.3、36.0、37.0、39.2处有特征峰。
可选的实施方案中,本公开提供的式(I)所示化合物的H晶型,以衍射角2θ角度表示的X-射线粉末衍射图,如附图9所示。
本公开提供一种制备式(I)所示化合物H晶型的方法,选自以下方法:
方法一
将式(I)所示化合物溶于溶剂13,搅拌析晶,所述的溶剂13选自醇类溶剂、醇类溶剂与水的混合溶剂、酮类溶剂或酯类溶剂;可选地,所述的醇类溶剂选自甲醇、乙醇、异丙醇、正丙醇,所述酮类溶剂选自丙酮、2-丁酮、甲基异丁基酮,所述酯类溶剂为乙酸乙酯;
方法二
将式(I)所示化合物与溶剂14混合,打浆析晶,所述溶剂14选自水或醚类溶剂;可选地,所述醚类溶剂选自甲基叔丁基醚或异丙醚;
方法三
a)将式(I)所示化合物溶于溶剂15;
b)加入溶剂16,析出晶体;
所述的溶剂15选自醇类溶剂、酮类溶剂、醚类溶剂,所述溶剂16选自低级烷烃、醚类溶剂或水;可选地,所述醇类溶剂选自异丙醇,所述酮类溶剂为丙酮,所述低级烷烃为正庚烷,所述醚类溶剂为四氢呋喃、异丙醚或甲基叔丁基醚。本公开另一方面提供一种式(I)所示化合物的可药用盐,所述的可药用盐选自盐酸盐、硫酸盐、甲磺酸盐、对甲苯磺酸盐、磷酸盐、柠檬酸盐或苹果酸盐。
可选的实施方案中,式(I)所示化合物与酸分子的比值选自约3∶1-1∶3,具体可选约1∶1、1∶2或1∶3。
本公开提供一种制备式(I)所示化合物的可药用盐的方法,包括游离碱与酸分子反应的步骤,所述的酸分子选自盐酸、硫酸、甲磺酸、对甲苯磺酸、磷酸、柠檬酸或苹果酸。
可选的实施方案中,本公开提供的制备式(I)所示化合物的可药用盐的方法,在溶剂作用下发生反应。
可选的实施方案中,所述溶剂为腈类溶剂、醇类溶剂、酯类溶剂、芳香烃类溶剂、醚类溶剂、酮类溶剂、取代的低级烷烃类溶剂。
可选的实施方案中,所述腈类溶剂为乙腈。
可选的实施方案中,所述的醇类溶剂为乙醇。
本公开提供的式(I)所示化合物的可药用盐可以为任意晶型或无定型。
本公开中所述取代的低级烷烃可选自硝基甲烷、二氯甲烷、三氯甲烷;所述的腈类溶剂选自乙腈或丙腈;所述的醇类溶剂指C1-C6的醇,可选甲醇、乙醇、正丙醇、异丙醇、正丁醇;所述的酮类溶剂选自丙酮、2-丁酮、甲基异丁酮;所述的醚类溶剂选自异丙醚、四氢呋喃、二氧六环、丙二醇甲醚;所述的酯类溶剂选自乙酸乙酯、乙酸甲酯、乙酸异丙酯;所述的低级烷烃选自正己烷或正庚烷。
本公开提供的制备方法中,溶剂的比例可以是式(I)所示化合物的0.1-100倍(w/v),具体可以是1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100,或任意两数之间的值。
本公开提供的晶型的制备方法包括固体与液体分离的步骤,具体可以是过滤、离心或将溶剂挥发完全。
本公开提供的晶型的制备方法可选包含干燥的步骤。
本公开还提供了一种药物组合物,其含有前述任意晶型或可药用盐,或其混合,和任选自药学上可接受的赋形剂中的药用辅料。
本公开还提供了一种药物组合物的制备方法,包括将前述任意晶型或可药用盐,与药学上可接受的赋形剂混合的步骤。
本公开还提供了前述任意晶型或可药用盐,或前述组合物在制备用于治疗或
预防与细胞周期蛋白-依赖性激酶相关疾病的药物中的用途。
本公开还提供了前述任意晶型或可药用盐,或前述组合物在制备用于治疗或预防自癌症的药物中的用途。
可选的实施方案中,所述的癌症选自乳腺癌、卵巢癌、膀胱癌、子宫癌、前列腺癌、肺癌、食道癌、头颈癌,肠癌、肾癌、肝癌、胰腺癌、胃癌和甲状腺癌。
本公开所述的“2θ或2θ角度”是指衍射角,θ为布拉格角,单位为°或度;每个特征峰2θ的误差范围为±0.2(包括超过1位小数的数字经过四舍五入后的情况),可以为-0.20、-0.19、-0.18、-0.17、-0.16、-0.15、-0.14、-0.13、-0.12、-0.11、-0.10、-0.09、-0.08、-0.07、-0.06、-0.05、-0.04、-0.03、-0.02、-0.01、0.00、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.10、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、0.19、0.20。
本公开中所述干燥温度一般为25℃~100℃,优选40℃~70℃,可以常压干燥,也可以减压干燥,压强<-0.08MPa。
本公开中所述的“赋形剂”包括但不限于任何已经被美国食品和药物管理局批准对于人类或家畜动物使用可接受的任何助剂、载体、助流剂、甜味剂、稀释剂、防腐剂、染料/着色剂、增香剂、表面活性剂、润湿剂、分散剂、助悬剂、稳定剂、等渗剂或乳化剂。
本公开所述的“打浆”是指利用物质在溶剂中溶解性差,但杂质在溶剂中溶解性好的特性进行纯化的方法,打浆提纯可以去色、改变晶型或去除少量杂质。
本公开晶型制备方法中所用的起始原料可以是任意形式化合物,具体形式包括但不限于:无定形、任意晶型、水合物、溶剂合物等。
本公开中式(I)所示化合物与酸的比值,±10%均属于合理误差范围内。可以为±9%、±8%、±7%、±6%、±5%、±4%、±3%、±2%或±1%。
PCT/CN2022/074509中公开的内容,一并引用到本公开中。
图1.式(I)所示化合物的无定型的XRPD谱图。
图2.式(I)所示化合物的A晶型的XRPD谱图。
图3.式(I)所示化合物的B晶型的XRPD谱图。
图4.式(I)所示化合物的C晶型的XRPD谱图。
图5.式(I)所示化合物的D晶型的XRPD谱图。
图6.式(I)所示化合物的E晶型的XRPD谱图。
图7.式(I)所示化合物的F晶型的XRPD谱图。
图8.式(I)所示化合物的G晶型的XRPD谱图。
图9.式(I)所示化合物的H晶型的XRPD谱图。
以下结合实施例用于进一步描述本公开,但这些实施例并非限制着本公开的范围。
实施例
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的单位给出。NMR的测定是用Bruker AVANCE NEO 500M核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6)、氘代氯仿(CDCl3)、氘代甲醇(CD3OD),内标为四甲基硅烷(TMS)。
MS的测定用Agilent 1200/1290 DAD-6110/6120 Quadrupole MS液质联用仪(生产商:Agilent,MS型号:6110/6120 Quadrupole MS)。
waters ACQuity UPLC-QD/SQD(生产商:waters,MS型号:waters ACQuity Qda Detector/waters SQ Detector)
THERMO Ultimate 3000-Q Exactive(生产商:THERMO,MS型号:THERMO Q Exactive)
高效液相色谱法(HPLC)分析使用Agilent HPLC 1200DAD、Agilent HPLC 1200VWD和Waters HPLC e2695-2489高压液相色谱仪。
手性HPLC分析测定使用Agilent 1260 DAD高效液相色谱仪。
高效液相制备使用Waters 2545-2767、Waters 2767-SQ Detecor2、Shimadzu LC-20AP和Gilson GX-281制备型色谱仪。
手性制备使用Shimadzu LC-20AP制备型色谱仪。
CombiFlash快速制备仪使用Combiflash Rf200(TELEDYNE ISCO)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
硅胶柱色谱法一般使用烟台黄海硅胶200~300目硅胶为载体。
激酶平均抑制率及IC50值的测定用NovoStar酶标仪(德国BMG公司)。
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成,或可购买自ABCR GmbH&Co.KG,Acros Organics,Aldrich Chemical Company,韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中无特殊说明,反应均能够在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
氢气氛是指反应瓶连接一个约1L容积的氢气气球。
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。
氢化反应通常抽真空,充入氢气,反复操作3次。
微波反应使用CEM Discover-S 908860型微波反应器。
实施例中无特殊说明,溶液是指水溶液。
实施例中无特殊说明,反应的温度为室温,为20℃~30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC),反应所使用的展开剂,纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括:A:二氯甲烷/甲醇体系,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
本公开中实验所用仪器的测试条件:
1、差示扫描量热仪(Differential Scanning Calorimeter,DSC)
仪器型号:Mettler Toledo DSC 3+STARe System
吹扫气:氮气;氮气吹扫速度:50mL/min
升温速率:10.0℃/min
温度范围:25-350℃或25-300℃
2、X-射线粉末衍射谱(X-ray Powder Diffraction,XRPD)
仪器型号:BRUKER D8Discover X-射线粉末衍射仪
射线:单色Cu-Kα射线(λ=1.5406)
扫描方式:θ/2θ,扫描范围(2θ范围):3~45°
电压:40kV,电流:40mA
3、热重分析仪(Thermogravimetric Analysis,TGA)
仪器型号:Mettler Toledo TGA2
吹扫气:氮气;氮气吹扫速度:50mL/min
升温速率:10.0℃/min
温度范围:30-350℃或30-300℃
4、DVS为动态水分吸附
检测采用Surface Measurement Systems advantage 2,在25℃,湿度从50%-95%-0%-95%-50%RH,步进为10%,判断标准为每个梯度质量变化dM/dT小于0.002%,TMAX 360min,循环两圈。
实施例1.游离态无定形的制备
将式(I)所示化合物10mg加入到0.5mL水中,室温下搅拌,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为无定形,XRPD谱图如图1所示。
实施例2.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL乙酸异丙酯中溶清,降至5℃,搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型A,XRPD谱图如图2所示,其特征峰位置如表1所示。DSC
谱图显示,吸热峰峰值87.79℃、254.08℃。TGA谱图显示,30-150℃失重10.07%。
表1
实施例3.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL乙酸乙酯中溶清,降至5℃,搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型A。
实施例4.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL甲基异丁基酮中溶清,降至5℃,搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型A。
实施例5.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL丙酮中溶解,加入0.6ml异丙醚,搅拌析晶,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型A。
实施例6.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL甲基异丁基酮中溶解,加入0.6ml异丙醚,搅拌析晶,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型A。
实施例7.游离态A晶型的制备
将式(I)所示化合物10mg加入到0.05mL乙酸乙酯中溶解,加入0.8ml甲基叔丁基醚,挥发析晶。经X-射线粉末衍射检测,该产物为晶型A。
实施例8.游离态B晶型的制备
将式(I)所示化合物10mg加入到0.05mL的硝基甲烷中溶清,室温下搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型B,XRPD谱图如图3所示,其特征峰位置如表2所示。DSC谱图显示,吸热峰峰值154.21℃、254.73℃。TGA谱图显示,30-150℃失重4.42%。
表2
实施例9.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.05mL的二氯甲烷中溶清,挥发析晶,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型C,XRPD谱图如图4所示,其特征峰位置如表3所示。DSC谱图显示,吸热峰峰值125.96℃、253.40℃。TGA谱图显示,30-150℃失重4.37%。
表3
实施例10.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.05mL的1,2-二氯乙烷中溶清,挥发析晶,得到固体。经X-射线粉末衍射检测,将该产物为晶型C。
实施例11.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.05mL的甲基异丁基酮中溶清,挥发析晶,得到固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例12.游离态C晶型的制备
将式(I)所示化合物10mg加入到1mL的对二甲苯中,搅拌析晶,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例13.游离态C晶型的制备
将式(I)所示化合物10mg加入到1mL的甲苯中,搅拌析晶,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例14.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.1mL的异丙醇中,加入1mL异丙醚后搅拌析出固体,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例15.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.1mL的丙酮中,加入1mL异丙醚后搅拌析出固体,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例16.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.1mL的ACN(乙腈)中,加入1mL异丙醚后搅拌析出固体,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例17.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.1mL的THF(四氢呋喃)中,加入1mL异丙醚后搅拌析出固体,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例18.游离态C晶型的制备
将式(I)所示化合物10mg加入到0.1mL的EtOH中,加入1mL异丙醚后搅拌析出固体,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型C。
实施例19.游离态D晶型的制备
将式(I)所示化合物10mg加入到1mL的异丙醚中,60℃下搅拌2h,离心后真空干燥得固体。经X-射线粉末衍射检测,将该产物定义为晶型D,XRPD谱图如图5所示,其特征峰位置如表4所示。DSC谱图显示,吸热峰峰值196.66℃。TGA谱图显示,30-150℃失重0.63%。
表4
实施例20.游离态D晶型的制备
将式(I)所示化合物100mg加入到10mL的异丙醚中,加入约1~2mg晶种,60℃下打浆2h,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例21.游离态D晶型的制备
将式(I)所示化合物50mg加入到0.1mL的乙醇中,60℃搅拌溶清,加入0.4mL异丙醚,再加入1~2mg晶型D晶种,60℃搅拌2h固体析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例22.游离态D晶型的制备
将式(I)所示化合物50mg加入到0.1mL的甲醇中,60℃搅拌溶清,加入0.4mL异丙醚,再加入1~2mg晶型D晶种,60℃搅拌2h固体析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例23.游离态D晶型的制备
将式(I)所示化合物700mg加入到1.4mL乙醇,60℃搅拌溶清,加入4.2mL异丙醚,再加入1~2mg晶型D晶种,60℃搅拌2h固体析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例24.游离态D晶型的制备
将式(I)所示化合物10mg加入到0.4mL的乙醇/异丙醚(1/20),60℃搅拌溶清,继续搅拌1h固体析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例25.游离态D晶型的制备
将式(I)所示化合物10mg加入到0.4mL的甲醇/异丙醚(1/20),60℃搅拌溶清,继续搅拌1h固体析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型D。
实施例26.游离态E晶型的制备
将式(I)所示化合物10mg加入到0.05mL乙腈溶清,降温至5℃,低温下搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型E,XRPD谱图如图6所示,其特征峰位置如表5所示。DSC谱图显示,吸热峰峰值35.46℃、137.39℃。TGA谱图显示,30-160℃失重6.04%。
表5
实施例27.游离态E晶型的制备
将式(I)所示化合物100mg加入到0.5mL的丙酮中溶清,加入3mL异丙醚,降温至5℃,搅拌析晶,过滤,收集滤饼,真空干燥,得到固体,经X-射线粉末衍射检测,该产物为晶型E。
实施例28.游离态F晶型的制备
将式(I)所示化合物100mg加入到0.5mL的甲基异丁基酮中溶清,室温下搅拌析晶,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型F,XRPD谱图如图7所示,其特征峰位置如表6所示。DSC谱图显示,吸热峰峰值32.47℃、137.02℃。TGA谱图显示,30-160℃失重6.99%。
表6
实施例29.游离态F晶型的制备
将式(I)所示化合物100mg加入到2mL的四氢呋喃中,60℃下搅拌溶清,加入10mL的异丙醚和F晶型晶种,60℃搅拌2h固体析出,过滤,收集滤饼,真空干燥,得到固体,经X-射线粉末衍射检测,该产物为晶型F。
实施例30.游离态G晶型的制备
将式(I)所示化合物50mg加入0.1mL的甲醇和0.4mL的异丙醚溶剂溶清,60℃搅拌2h析出固体,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型G,XRPD谱图如图8所示,其特征峰位置如表7所示。DSC谱图显示,吸热峰峰值173.41℃。TGA谱图显示,30-190℃失重1.18%。
表7
实施例31.游离态H晶型的制备
将式(I)所示化合物10mg加入0.05mL的乙醇中,60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,将该产物定义为晶型H,XRPD谱图如图9所示,其特征峰位置如表8所示。DSC谱图显示,吸热峰峰值206.30℃。TGA谱图显示,33-218℃失重0.29%。
表8
实施例32.游离态H晶型的制备
将式(I)所示化合物10mg加入0.05mL的异丙醇中,60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例33.游离态H晶型的制备
将式(I)所示化合物10mg加入0.05mL的正丙醇中,60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例34.游离态H晶型的制备
将式(I)所示化合物10mg加入0.05mL的2-丁酮中,60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例35.游离态H晶型的制备
将式(I)所示化合物10mg加入0.05mL的甲醇/水=1/1溶剂中,60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例36.游离态H晶型的制备
将式(I)所示化合物10mg加入0.25mL的乙酸乙酯溶剂中60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例37.游离态H晶型的制备
将式(I)所示化合物10mg加入0.25mL的甲基异丁基酮溶剂中60℃加热搅拌溶清,于50℃-5℃下混悬升降温搅拌析出,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例38.游离态H晶型的制备
将式(I)所示化合物10mg加入1mL的水中,60℃加热搅拌不溶,于50℃-5℃下混悬升降温搅拌打浆,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例39.游离态H晶型的制备
将式(I)所示化合物10mg加入1mL的甲基叔丁基醚中,60℃加热搅拌不溶,于50℃-5℃下混悬升降温搅拌打浆,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例40.游离态H晶型的制备
将式(I)所示化合物10mg加入1mL的异丙醚中,60℃加热搅拌不溶,于50℃-5℃下混悬升降温搅拌打浆,过滤,收集滤饼,真空干燥,得到固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例41.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.15mL异丙醇中60℃搅拌溶解,加入1mL水后搅拌析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例42.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.15mL异丙醇中60℃搅拌溶解,加入1mL正庚烷后搅拌析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例43.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.15mL异丙醇中60℃搅拌溶解,加入1mL异丙醚后搅拌析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例44.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.1mL丙酮中60℃搅拌溶解,加入1mL水后析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例45.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.1mL丙酮中60℃搅拌溶解,加入1mL正庚烷后析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例46.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.1mL丙酮中60℃搅拌溶解,加入1mL异丙醚后析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例47.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.05mL四氢呋喃中60℃搅拌溶解,加入1mL甲基叔丁基醚后析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例48.游离态H晶型的制备
将式(I)所示化合物10mg加入到0.05mL四氢呋喃中60℃搅拌溶解,加入1mL异丙醚后析出,离心后真空干燥得固体。经X-射线粉末衍射检测,该产物为晶型H。
实施例49.游离态晶型的引湿性研究
采用Surface Measurement Systems intrinsic DVS,在25℃,考察湿度范围为0%-95%,步进为10%,判断标准为每个梯度质量变化dM/dT小于0.002%,TMAX360min,循环两圈。
表9
实施例50.晶型影响因素稳定性研究
将游离态样品敞口平摊放置,分别考察在光照(4500Lux)、高温(40℃、60℃)、高湿(RH 75%、RH 92.5%)条件下样品的稳定性,取样考察期为30天。
表10
表11
表12
表13
表14
表15
影响因素实验结果显示:晶型D/E/F/G/H、游离态无定型在高温、高湿下化学稳定性良好。晶型D/E/F/G/H、游离态无定型物理稳定性良好。
实施例51.晶型长期/加速稳定性
将游离态样品用铝箔袋密封,分别放置25℃/60%RH和40℃/75%RH条件考察稳定性,结果如下所示。
表16
实验结果表明,晶型H在长期加速条件下放置3个月,物理和化学稳定性良好。晶型D、晶型E、晶型F、晶型G在长期加速条件下放置6个月,物理和化学稳定性良好。游离态无定形加速潮解,其他条件下物理和化学稳定性良好。
实施例52.盐酸盐的制备
将式(I)所示化合物100mg加入到2mL乙腈中,加入115.3μl的2M盐酸乙醇溶液搅拌5h,样品溶清,加入5ml异丙醚搅拌析出,离心,真空干燥得固体。离子色谱结果显示氯离子含量为6.7%。
实施例53.硫酸盐的制备
将式(I)所示化合物100mg加入到2mL乙腈中,加入115.3μl的2M硫酸乙醇溶液搅拌5h,样品溶清,加入5ml异丙醚搅拌析出,离心,真空干燥得固体。离子色谱结果显示硫酸根离子含量为14.9%。
实施例54.甲磺酸盐的制备
将式(I)所示化合物100mg加入到2mL乙腈中,加入115.3μl的2M甲磺酸乙醇溶液搅拌5h,样品溶清,加入5ml异丙醚搅拌析出,离心,真空干燥得固体。离子色谱结果显示甲磺酸根离子的含量为17.8%。
实施例55.对甲苯磺酸盐的制备
将式(I)所示化合物100mg加入到2mL乙腈中,加入115.3μl的2M对甲苯磺酸乙醇溶液搅拌5h,样品溶清,加入5ml异丙醚搅拌析出,离心,真空干燥得固体。离子色谱结果显示对甲苯磺酸根离子的含量为34.3%。
实施例56.磷酸盐的制备
将式(I)所示化合物10mg加入到0.2mL乙腈中,加入11.5μl的2M磷酸乙醇溶液搅拌5h,离心,真空干燥得固体。
实施例57.柠檬酸盐的制备
将式(I)所示化合物10mg加入到0.2mL乙腈中,加入11.5μl的2M柠檬酸乙醇溶液搅拌5h,离心,真空干燥得固体。
实施例58.苹果酸盐的制备
将式(I)所示化合物10mg加入到0.2mL乙腈中,加入11.5μl的2M柠檬酸乙醇溶液搅拌5h,离心,真空干燥得固体。
实施例59.
(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇异构体1
第一步
6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-甲醛4a
氮气氛下,依次将6-溴-8-氟-2,3-二甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯(2.0g,7mmol)、二氧化硒(3.1g,28mmol)加入到30mL 1,4-二氧六环中。95℃条件下反应8小时。反应液冷却至室温,过滤,收集滤液,减压浓缩后残余物用C-18反相色谱法纯化得到标题化合物4a(930mg,产率:44%)。
MS(ESI)m/z 299.1,301.1[M+H]+
第二步
1-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)乙烷-1-醇4b
氮气氛下,将6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-甲醛(930mg,3.1mmol)溶于20mL四氢呋喃中。降温至-20℃,滴加甲基溴化镁四氢呋喃溶液(3mol/L,1.5ml,4.5mmol),并在-20℃条件下反应4小时。加入5ml水淬灭反应,反应液减压浓缩后残余物用C-18反相色谱法纯化得到标题化合物4b(830mg,产率:85%)。
MS(ESI)m/z 315.2,317.2[M+H]+
第三步
1-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)乙烷-1-酮4c
室温下,将1-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)乙烷-1-酮(600mg,1.9mmol)溶于20mL四氢呋喃中,加入戴斯马丁氧化剂(2.0g,4.8mmol)。加热至80℃并反应2小时,反应液冷却至室温,过滤,收集滤液,减压浓缩后残余物用C-18反相色谱法纯化得到标题化合物4c(350mg,产率:59%)。
MS(ESI)m/z 313.1,315.1[M+H]+
第四步
2-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)丙烷-2-醇4d
氮气氛下,将1-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)乙烷-1-酮(350mg,1.1mmol)溶于20mL四氢呋喃中。降温至-20℃,滴加甲基溴化镁四氢呋喃溶液(3mol/L,0.7ml,2.1mmol),并在-20℃条件下反应4小时。加入5ml水淬灭反应,反应液减压浓缩后残余物用C-18反相色谱法纯化得到标题化合物4d(260mg,产率:71%)。
MS(ESI)m/z 329.2,331.2[M+H]+
第五步
2-(6-(2,5-二氯嘧啶-4-基)-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)丙烷-2-醇4e
氮气氛下,依次将化合物2-(6-溴-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)丙烷-2-醇(260mg,0.8mmol)、联硼酸频那醇酯(305mg,1.2mmol)、醋酸钾(157mg,1.6mmol)、[1,1′-双(二苯基膦基)二茂铁]二氯化钯(117mg,0.2mmol)溶于5mL 1,4-二氧六环中。100℃条件下反应2小时。反应液冷却至室温,加入1,3,5,7-四甲基-6-苯基-2,4,8-三氧杂-6-磷酰金刚烷(58mg,0.2mmol)、碳酸钾(221mg,1.6mmol)、2,4-二氯-5-氟嘧啶(220mg,1.2mmol)、三(二亚苄基丙酮)二钯(183mg,0.2mmol)和1mL水,80℃条件下反应1小时。反应液冷却至室温,过滤,收集滤液,减压浓缩后残余物用C-18反相色谱法纯化得到标题化合物4e(129mg,产率:41%)。
MS(ESI)m/z 397.3[M+H]+
第六步
(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇异构体1
(3S,4R)-4-((5-氯-4-((R)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇异构体2
氮气氛下,依次将2-(6-(2,5-二氯嘧啶-4-基)-8-氟-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-2-基)丙烷-2-醇(124mg,0.31mmol)、(3S,4R)-4-氨基四氢-2H-吡喃-3-醇(19mg,0.16mmol)、(S)-(-)-2,2″-双(二苯膦基)-1,1″-联萘(118mg,0.5mmol)、醋酸钯(14mg,0.06mmol)溶于5mL四氢呋喃中。加入碳酸铯(202mg,0.62mmol),85℃条件下反应3小时。反应液冷却至室温,过滤,收集滤液,减压浓缩后残余物用C-18反相色谱法纯化得到粗品混合物4f,粗品通过手性拆分[Column:
DAICEL CHIRALPAK AD(250mm*30mm,10μm),Condition:0.1%NH3·H2O ETOH,Begin B:40%;End B:40%;FlowRate(ml/min):60)]得到标题化合物isomer 1(25.2mg,产率:17%)和标题化合物isomer 2(22mg,产率:15%)。
分析方法
Column:DAICEL CHIRALCEL AD-3(100mm*4.6mm,3μm);
Mobile phase:A:CO2B:ethanol(0.05%DEA),Gradient:from 5%to 40%ofB in 2min and hold 40%for 1.2min,then 5%of B for 0.8min;
FlowRate:4mL/min;
ABPR:1500psi;
Temperature:35℃.
将保留时间为1.887min的化合物定义为异构体2;
MS(ESI)m/z 478.1[M+H]+
1H NMR(400MHz,DMSO-d6)δ=8.37(s,1H),7.45(br s,1H),6.92(d,J=11.3Hz,1H),5.82(br s,1H),5.23(q,J=6.4Hz,1H),4.47(d,J=11.0Hz,1H),4.22(br d,J=11.3Hz,1H),3.89-3.67(m,3H),3.39-3.25(m,4H),3.03(br t,J=10.2Hz,1H),1.95(br d,J=10.5Hz,1H),1.68(s,3H),1.62(s,3H),1.45(d,J=6.5Hz,3H)
将保留时间为2.078min的化合物定义为异构体1;
MS(ESI)m/z 478.1[M+H]+
1H NMR(400MHz,DMSO-d6)δ=8.37(s,1H),7.45(br s,1H),6.92(d,J=11.5Hz,1H),5.82(s,1H),5.29-5.19(m,1H),4.93(d,J=5.5Hz,1H),4.47(d,J=11.3Hz,1H),4.21(br d,J=10.3Hz,1H),3.85-3.75(m,3H),3.53-3.40(m,2H),3.03(br t,J=10.4Hz,1H),1.94(br s,1H),1.67(s,3H),1.62(s,3H),1.45(d,J=6.5Hz,3H),1.06(t,J=7.0Hz,1H)
生物学评价
以下结合测试例进一步描述解释本发明,但这些实施例并非意味着限制本发明的范围。
测试例1、公开化合物对细胞周期蛋白-依赖性激酶活性检测
1、实验材料
化合物A为WO 2019/207463A1的example A94,参照该专利公开的方法合成得到。
2、激酶活性测试(CDK4/CyclinD1,CDK6/CyclinD3)Mobility shift assay测激酶活性
体外CDK激酶活性通过Mobility Shift Assay的方法进行测试。实验中,受试化合物对CDK活性抑制的测试的起始浓度为300nM,3倍稀释,共10个浓度,复孔测试。采用化合物Staurosporine作为标准对照。
配制1倍激酶缓冲液(CDK2)(50mM HEPES,pH 7.5,0.0015%Brij-35),1倍激酶缓冲液(CDK4)(20mM HEPES,pH 7.5,0.01%Triton X-100),终止液(100mM HEPES,pH 7.5,0.015%Brij-35,0.2%Coating Reagent#3,50mM EDTA)。将适量激酶加入1倍激酶缓冲液中配制2.5倍酶溶液;配制化合物测试浓度相应5倍化合物稀释液(1倍激酶缓冲液,10%DMSO);将适量FAM标记的多肽和ATP加入1倍激酶缓冲液,配制2.5倍底物溶液。在384孔反应板的反应孔中加入5μl5倍化合物稀释液及10μl 2.5倍酶溶液,混匀后室温孵育10分钟;然后向384孔板中加入10μl 2.5倍底物溶液,1000rpm离心1分钟;反应板在28℃下孵育60分钟(生化培养箱型号:SPX-100B-Z);向384孔反应板中加30μl终止液终
止反应,1000rpm离心1分钟;最后在Caliper EZ Reader II上读取转化率数据(激发波长:400nm,发射波长:445nm和520nm)。
化合物的IC50值用XLFit excel add-in version 5.4.0.8拟合。拟合公式:
Y=Bottom+(Top-Bottom)/(1+(IC50/X)^HillSlope)。
3、激酶活性测试(CDK1/CyclinB,CDK 9/CyclinT1)
体外CDK(CDK2、CDK9)激酶活性测试的起始浓度为1uM,3倍稀释,共10个浓度,复孔测试。采用化合物PHA-793887作为对照化合物。
配制1x激酶反应缓冲液(40mM Tris-HCl,pH7.4,20mM Mg2Cl2,0.1mg/ml BSA,50uM DTT),1倍体积的5x激酶反应缓冲液和4倍体积的水,并加入DTT(终浓度50uM)。用Echo655向反应板(784075,Greiner)每孔转移稀释好的化合物工作液50nL(DMSO终浓度为1%)。用封板膜封住反应板,1000g离心1分钟。用1x激酶反应缓冲液配制2x酶(0.3ng/uL CDK2/CyclinE1或CDK9/CyclinT1),每孔加入2.5uL上述激酶溶液,用封板莫封住反应板,1000g离心1分钟,室温放置10分钟。用1×激酶反应缓冲液配制2×激酶底物和ATP混合液,2×CDK2/CylinE1激酶底物为0.4mg/ml Histone H1和30μM ATP。向反应板中加入2.5μL 2×Histone H1和ATP混合液,1000g离心30秒,开始反应。激酶测试室温反应120分钟后,加入4μl ADP-Glo试剂,室温反应40分钟。然后加入8μl激酶检测试剂,室温反应40分钟,用Envision 2104读发光信号。数据分析如下
a)抑制百分率:%inhibition=100-(Signalcmpd-SignalAve_PC)/(SignalAve_VC-SignalAve_PC)×100.
SignalAve_PC:整板所有阳性对照孔的平均值。
SignalAve_VC:整板所有阴性对照孔的平均值。
b)化合物IC50:用GraphPad 8.0,利用以下非线性拟合公式来计算得到。
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
X:化合物浓度log值;Y:化合物抑制百分率
本公开化合物的CDK(CDK1、CDK4、CDK6、CDK9)激酶生化抑制活性通过以上的试验进行测定,测得的IC50值见表17、表18。
表17.
表18.
测试例2、CYP抑制实验
使用150个供体混合人肝微粒体(购自Corning,货号452117)评估人主要5个CYP亚型(CYP1A2、CYP2C9、CYP2C19、CYP2D6、CYP3A4)的代表性底物代谢反应。通过液相色谱串联质谱(LC/MS/MS)测定不同浓度待测化合物对非那西丁(CYP1A2)、双氯芬酸钠(CYP2C9)、S-美芬妥英(CYP2C19)、丁呋洛尔盐酸盐(CYP2D6)、咪达唑仑(CYP3A4/5)代谢反应的影响。
将30μM非那西丁、10μM双氯芬酸钠、35μM S-美芬妥英、5μM丁呋洛尔盐酸盐、3μM咪达唑仑、1mM NADPH、待测化合物(浓度分别为0.1、0.3、1、3、10、30μmol/L)或阳性化合物或空白对照与混合人肝微粒体(0.2mg/mL)的反应体系200μL(100mmol/L磷酸盐缓冲液,pH 7.4,含体积比分别为0.3%的DMSO、0.6%的乙腈、0.1%的甲醇)在37℃孵育5分钟。然后加入200μL含3%甲酸及40nM内标维拉帕米的乙腈溶液,4000rpm离心50分钟。置于冰上冷却20分钟,再4000rpm离心20分钟析出蛋白。取200μL上清液进行LC/MS/MS分析。
峰面积根据色谱图计算。残余活性比例(%)用如下公式进行计算:
峰面积比例=代谢产物峰面积/内标峰面积
残余活性比例(%)=待测化合物组的峰面积比例/空白组的峰面积比例
CYP半数抑制浓度(IC50)通过Excel XLfit 5.3.1.3计算得到。
测得的CYP半数抑制浓度(IC50)数值见下表19。
表19.本发明化合物对CYP的半数抑制浓度(IC50)
测试例3、溶解度测试实验
测定化合物在pH7.4的磷酸盐缓冲液中的热动力学溶解度。样品上清液和已知浓度的标准品都通过LC/MS/MS来检测。
1、材料和试剂
化合物A(化合物A为WO 2019/207463A1的example A94,参照该专利公开的方法合成得到)。
NaH2PO4·2H2O(分析纯),NaH2PO4(分析纯),NaOH(分析纯)。
1.5mL平底玻璃管(BioTech Solutions);模塑的聚四氟乙烯盖子(BioTech Solutions),聚四氟乙烯包被的搅拌棒(BioTech Solutions),Eppendorf舒适型恒温混匀器及96孔深孔板。
2、pH7.4的0.01M磷酸纳缓冲液的制备
称量15.6g的NaH2PO4·2H2O放入1L玻璃瓶内,加入1L去离子水溶解。溶液PH大概为4.7,然后用10M NaOH调节PH值到7.4。
3、溶解度测定过程
每个化合物准确称量1mg的粉末,放入玻璃管内,上述玻璃管内加入PH7.4的磷酸盐缓冲液,加入量为每毫克加1mL。每个玻璃管加入一个搅拌棒,再盖上盖子,把装有玻璃管的样品盘放入Eppendorf舒适型恒温混匀器中,25℃,1100rpm孵育24小时,孵育结束后打开盖子,用磁铁吸出搅拌棒,并记录每个玻璃管内的现象,将板子25℃,4000rpm离心30分钟。吸取750μL上清液。枪头用乙腈洗5秒,再用纯水洗5秒。然后排出前50μL废液,剩下700μL加入到另一个装有玻璃管的96孔样品盘中,再离心30分钟(25℃,4000,rpm),吸取10μL二次离心的样品加入990μL的含内标的乙腈和水(1∶1)的混合液中(100倍样品),吸取10μL稀释溶液加入990μL的含内标的乙腈和水(1∶1)的混合液中(10,000倍样品)。样品稀释倍数可能会根据溶解度值和LC/MS信号响应而改变。
表20.现象的记录和稀释倍数
4、标准品的制备
准确称量1mg化合物粉末,各加入一只玻璃管内,每个玻璃管内加入DMSO,加入量为每毫克加1mL。每个玻璃管加入一个搅拌棒,再盖上盖子,把装有标准品玻璃管的盘放入Eppendorf舒适型恒温混匀器中,25℃,1,100转孵育2小时让粉末充分溶解,观察固体是否完全溶解,记录下化合物在DMSO溶液中不能完全溶解的。吸取10μL 1mg/mL的标准品加入990μL的含内标的乙腈和水(1∶1)的混合液中,得到10μg/mL的标准品。吸取10μL 10μg/mL的标准品加入990μL的含内标的乙腈和水(1∶1)的混合液中,得到0.1μg/mL的标准品。样品稀释倍数可能会根据LC/MS信号响应而改变。样品通过LC/MS/MS进行分析。所有化合物单独进行测试。
5、数据计算
所有计算通过Microsoft Excel进行。样品通过LC/MS/MS进行分析,根据已知浓度的标准品来定量。通过以下公式计算待测化合物的溶解度:[Sample]=Area Ratio sample×DF sample×[STD]/Area Ratio STD
DF:稀释倍数。
表21.本发明部分化合物溶解度
测试例5、PXR诱导实验
1、评估待测化合物通过体外激活PXR从而诱导药物代谢酶活力的潜力。待测化合物通过体外激活PXR测量不同浓度的测试化合物(30、10、3.33、1.11、0.370及0.123μM)得到EC50值。阳性对照利福平的浓度为20、5、1.25、0.312、0.0781和0.195μM。
2、材料和试剂
1)DPX2(人类PXR基因和荧光报告基因与稳定转染到HepG2细胞中)细胞购自Puracyp(Carlsbad,CA)。
2)委托方提供待测化合物,对照药(利福平)购自Sigma(St.Louis,MO)。
3)CellTiter-FluorTM细胞活力检测试剂盒和One-Glo荧光检测试剂盒购自Promega(Madison,WI),胎牛血清(FBS)购自Corning(Manassas,VA),MTS3振荡器购自IKA Labortechnik(Staufen,Germany),DMEM、penicillin和streptomycin购自本地供应商HygromycinB and G418购自Merck(Darmstadt,Germany),细胞培养基和DPX2细胞购自Puracyp Inc。
3、实验步骤
3.1种板准备
1)加50mL FBS到450mL细胞培养基中。
2)DPX2细胞用T-75培养瓶在37℃,5%CO2,95%的相对湿度的孵箱中培养,在细胞长满培养瓶瓶底80-90%时消化细胞。
3)用8mL PBS清洗T-75培养的细胞表层,吸弃PBS,加入3mL胰酶,在37℃消化5分钟左右,或者直到细胞被消化下来悬浮在胰酶中,加入10mL过剩的含血清培养基中和胰酶。
4)将细胞悬液转至锥形底的离心管中,120g离心10分钟。用种板培养基将细胞悬浮并调浓度为4x 105cells/mL。在96孔细胞培养板中每孔加入稀释好的细胞100μL。将培养板放入孵箱,37℃孵育24小时,然后准备PXR激活实验。
3.2加药处理
1)用DMSO准备测试化合物和阳性化合物(利福平),用37℃的不含有血清的培养基稀释化合物。阳性对照利福平的终浓度是20、5、1.25、0.312、0.0781和0.195μM,待测化合物的最终浓度为30、10、3.33、1.11、0.370和0.123μM。DMSO的终浓度为0.1%。向含有1mL预孵育的培养基中加入1μL的DMSO做为溶剂对照组。
2)从孵箱中拿出细胞培养板,弃去培养基,在合适的孔加入100μL的待测化合物和阳性化合物,每组两个平行,将细胞板放入孵化器中孵育24小时。
3.3 PXR激活的定量测定
1)药物处理2天后,培养物可以做PXR激活定量检测。
2)将CellTiter-FluorTM细胞活力检测试剂盒和One-Glo Luciferase试剂平衡至室温。将GF-AFC(10μL)底物加入Assay Buffer(10mL)形成2X试剂,然后用10ml PBS稀释至1X;将ONE-Glo底物加入ONE-Glo Luciferase Assay缓冲液。
3)从孵箱中取出细胞培养板,弃去每个孔中的培养基,用PBS洗2遍,将1X的CellTiter-FluorTM试剂加入灭菌的加样槽,用排枪吸取50μL加入每个孔中,37℃孵育30分钟。
4)从孵化器中移出96孔细胞板,用酶标仪在激发波长400nm,发射波长505nm的荧光模式下进行测定每个孔的荧光值。
5)将ONE-Glo试剂倒入加样槽,然后用排枪取50uL加入每孔,轻轻混匀试剂,放置室温下孵育混匀5分钟。孵育完成后使用光度计读取每个孔的发光值。
4、细胞诱导值计算
4.1细胞活力
细胞活率计算公式:
Percent cell viability(%)=I(sample)/(I(vehicle)x 100
I(sample)是样品的荧光强度,I(vehicle)是指0.1%DMSO对细胞的荧光强度。
4.2细胞诱导值计算
所有的数据都用Microsoft Excel来计算。
荧光素酶的活力用RFU/RLU来体现,RLU是每个化合物每个浓度的两个平行的平均发光强度值,RFU是每个化合物每个浓度的两个平行的平均荧光强度。
诱导倍数计算公式:
表22.部分测得PXR诱导值
Claims (23)
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在9.6、10.0、11.7、15.0、21.1、21.7处有特征峰;优选地,在7.8、9.6、10.0、11.7、15.0、18.9、19.4、20.1、21.1、21.7处有特征峰;最优选地,在7.8、9.6、10.0、11.7、15.0、18.9、19.4、20.1、21.1、21.7、23.5、26.7、29.4处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.3、15.1、20.9、22.8、23.7处有特征峰;优选地,在7.4、11.3、14.3、15.1、16.3、18.0、20.0、20.9、22.8、23.2、23.7、25.1、26.0处有特征峰;最优选地,在7.4、9.5、11.3、12.4、12.8、13.7、14.3、15.1、16.3、18.0、19.2、20.0、20.9、22.8、23.2、23.7、25.1、26.0、26.8、28.2、30.4、32.7、33.6、34.3、35.5、38.4、39.0、40.5处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的C晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、10.1、12.0、15.0处有特征峰;优选地,在4.8、7.6、10.1、12.0、15.0、19.7、21.2、23.5处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的D晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在10.0、10.5、17.0、18.7、23.9处有特征峰;优选地,在10.0、10.5、11.0、13.4、15.9、17.0、18.3、18.7、20.8、23.9、28.0处有特征峰;最优选地,在10.0、10.5、11.0、12.5、13.4、15.9、17.0、18.3、18.7、20.1、20.8、22.3、23.9、26.7、28.0、30.5、31.0、32.1、33.1、33.8、34.6处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的E晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.8、11.4、14.4、15.1、16.4、19.3、22.9处有特征峰;优选地,在4.8、7.4、11.4、14.4、15.1、16.4、17.9、19.3、19.9、20.9、22.9、23.5处有特征峰;更优选地,在4.8、7.4、9.6、11.4、14.4、 15.1、16.4、17.9、19.3、19.9、20.9、22.9、23.5、24.2、25.2、25.9、26.8、30.5处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的F晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.1、11.4、14.3、15.1、15.7、19.2、22.0处有特征峰;优选地,在9.1、11.1、11.4、13.3、14.3、15.1、15.7、16.6、17.9、19.2、20.0、21.1、22.0、23.6、24.6、26.1处有特征峰;最优选地,在4.8、9.1、9.8、11.1、11.4、12.0、13.3、14.3、15.1、15.7、16.6、17.9、19.2、20.0、21.1、22.0、22.5、23.6、24.2、24.6、25.2、25.6、26.1、28.7、30.3、35.0处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的G晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.3、15.3、16.1、17.9、18.6、20.8处有特征峰;优选地,在11.3、15.3、16.1、17.9、18.6、20.8、22.8、23.1、23.8、25.8处有特征峰;最优选地,在9.1、11.3、12.6、13.8、14.7、15.3、16.1、17.0、17.5、17.9、18.6、19.6、20.8、21.6、22.8、23.1、23.8、24.3、25.3、25.8、27.3、27.8、29.3、30.8、32.3、33.6、34.5、35.0处有特征峰。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的H晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在11.7、12.3、15.5、19.4、22.3处有特征峰;优选地,在11.7、12.3、15.5、18.2、19.4、21.3、22.3、24.9、27.1、28.1处有特征峰;最优选地,在10.1、11.7、12.3、12.8、13.4、15.5、17.1、18.2、19.4、20.5、21.3、22.3、23.2、24.5、24.9、25.6、26.4、27.1、28.1、28.4、30.7、31.2、32.1、33.3、36.0、37.0、39.2处有特征峰。
- 根据权利要求1至8任一项所述的晶型,其特征在于所述2θ值误差范围为±0.2。
- 一种制备权利要求1或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的A晶型的方法,包含以下步骤:方法一a)将式(I)所示化合物溶于溶剂1;b)加入溶剂2,析出晶体;所述溶剂1选自酮类溶剂或酯类溶剂,所述的溶剂2为醚类溶剂;优选地,所述酮类溶剂选自丙酮或甲基异丁基酮,所述的酯类溶剂为乙酸乙酯,所述的醚类溶剂选自异丙醚或甲基叔丁基醚;方法二将式(I)所示化合物溶于溶剂3,搅拌析晶,所述的溶剂3选自酯类溶剂和酮类溶剂;优选地,所述的酯类溶剂选自乙酸乙酯、乙酸异丙酯,所述酮类溶剂为甲基异丁基酮。
- 一种制备权利要求2或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的B晶型的方法,包括以下步骤:将式(I)所示化合物溶于取代的低级烷烃,搅拌析晶;优选地,所述的取代的低级烷烃为硝基甲烷。
- 一种制备权利要求3或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的C晶型的方法,选自以下方法:方法一将式(I)所示化合物溶于溶剂4,挥发析晶,所述溶剂4选自取代低级烷烃或酮类溶剂;优选地,所述的取代低级烷烃选自二氯甲烷或1,2-二氯乙烷,所述的酮类溶剂为甲基异丁基酮;方法二将式(I)所示化合物溶于溶剂5,搅拌析晶,所述的溶剂5选自芳香烃类溶剂;优选地,所述的芳香烃类溶剂选自对二甲苯或甲苯;方法三a)将式(I)所示化合物溶于溶剂6;b)加入溶剂7,析出晶体;所述溶剂6选自醇类溶剂、酮类溶剂、腈类溶剂、醚类溶剂,所述溶剂7为醚类溶剂;优选地,所述醇类溶剂选自异丙醇或乙醇,所述酮类溶剂为丙酮,所述腈类溶剂为乙腈,所述醚类溶剂选自四氢呋喃或异丙醚。
- 一种制备权利要求4或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的D晶型的方法,包括以下步骤:将式(I)所示化合物溶于溶剂8, 搅拌析晶,所述溶剂8为醚类溶剂,或醇类溶剂与醚类溶剂的混合溶剂;优选地,所述的醇类溶剂为甲醇、乙醇或异丙醇,所述醚类溶剂为异丙醚。
- 一种制备权利要求5或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的E晶型的方法,选自以下方法:方法一将式(I)所示化合物溶于溶剂9,搅拌析晶,所述溶剂9为腈类溶剂,优选地,所述的腈类溶剂为乙腈;方法二a)将式(I)所示化合物溶于溶剂10;b)加入溶剂11,析出晶体;所述的溶剂10选自酮类溶剂,所述的溶剂11为醚类溶剂;优选地,所述的酮类溶剂为丙酮,所述的醚类溶剂为异丙醚。
- 一种制备权利要求6或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的F晶型的方法,选自以下方法:方法一将式(I)所示化合物溶于溶剂12,搅拌析晶,所述溶剂12为酮类溶剂;优选地,所述的酮类溶剂为甲基异丁基酮;方法二将式(I)所示化合物溶于四氢呋喃,溶清,加入异丙醚和F晶型的晶种,析出晶体。
- 一种制备权利要求7或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的G晶型的方法,包括以下步骤:将式(I)所示化合物溶于醇类溶剂和醚类溶剂的混合溶剂,搅拌析晶;优选地,所述醇类溶剂选自甲醇,所述醚类溶剂为异丙醚。
- 一种制备权利要求8或9所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的H晶型的方法,选自以下方法:方法一将式(I)所示化合物溶于溶剂13,搅拌析晶,所述的溶剂13选自醇类溶剂、醇类溶剂与水的混合溶剂、酮类溶剂、酯类溶剂;优选地,所述的醇类溶剂选自甲醇、乙醇、异丙醇、正丙醇,所述酮类溶剂选自丙酮、2-丁酮、甲基异丁基酮,所述酯类溶剂为乙酸乙酯;方法二将式(I)所示化合物与溶剂14混合,打浆析晶,所述溶剂14选自水、醚类溶剂;优选地,所述醚类溶剂选自甲基叔丁基醚或异丙醚;方法三a)将式(I)所示化合物溶于溶剂15;b)加入溶剂16,析出晶体;所述的溶剂15选自醇类溶剂、酮类溶剂、醚类溶剂,所述溶剂16选自低级烷烃、醚类溶剂或水;优选地,所述醇类溶剂选自异丙醇,所述酮类溶剂为丙酮,所述低级烷烃为正庚烷,所述醚类溶剂为四氢呋喃、异丙醚或甲基叔丁基醚。
- 化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的可药用盐,所述的可药用盐选自盐酸盐、硫酸盐、甲磺酸盐、对甲苯磺酸盐、磷酸盐、柠檬酸盐或苹果酸盐。
- 一种制备权利要求18所述的化合物(3S,4R)-4-((5-氯-4-((S)-8-氟-2-(2-羟基丙烷-2-基)-3-甲基-3,4-二氢-5-氧杂-1,2a-二氮杂苊烯-6-基)嘧啶-2-基)氨基)四氢-2H-吡喃-3-醇的可药用盐的方法,包括游离碱与酸分子反应的步骤,所述的酸分子选自盐酸、硫酸、甲磺酸、对甲苯磺酸、磷酸、柠檬酸或苹果酸。
- 一种药物组合物,含有权利要求1-9或18任一项所述的晶型或化合物,和任选自药学上可接受的赋形剂。
- 一种药物组合物的制备方法,包括将权利要求1-9或18任一项所述的晶型或化合物与药学上可接受的赋形剂混合的步骤。
- 权利要求1-9或18任一项所述的晶型或化合物,或权利要求20所述的组合物在制备用于治疗或预防与细胞周期蛋白-依赖性激酶相关疾病的药物中的用途。
- 权利要求1-9或18任一项所述的晶型或化合物,或权利要求20所述的组合物在制备用于治疗或预防癌症的药物中的用途;优选地,所述癌症选自乳腺癌、卵巢癌、膀胱癌、子宫癌、前列腺癌、肺癌、食道癌、头颈癌,肠癌、肾癌、肝癌、胰腺癌、胃癌和甲状腺癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210915848.1 | 2022-08-01 | ||
CN202210915848 | 2022-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024027631A1 true WO2024027631A1 (zh) | 2024-02-08 |
Family
ID=89848540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/110180 WO2024027631A1 (zh) | 2022-08-01 | 2023-07-31 | 一种稠三环类衍生物的晶型及制备方法 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202406912A (zh) |
WO (1) | WO2024027631A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110234652A (zh) * | 2016-12-22 | 2019-09-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物及其制备方法和用途 |
CN110818690A (zh) * | 2016-07-26 | 2020-02-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
CN112313219A (zh) * | 2018-04-26 | 2021-02-02 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
CN113698391A (zh) * | 2020-05-21 | 2021-11-26 | 上海拓界生物医药科技有限公司 | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 |
WO2022166799A1 (zh) * | 2021-02-03 | 2022-08-11 | 上海拓界生物医药科技有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
-
2023
- 2023-07-31 TW TW112128660A patent/TW202406912A/zh unknown
- 2023-07-31 WO PCT/CN2023/110180 patent/WO2024027631A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110818690A (zh) * | 2016-07-26 | 2020-02-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
CN110234652A (zh) * | 2016-12-22 | 2019-09-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物及其制备方法和用途 |
CN112313219A (zh) * | 2018-04-26 | 2021-02-02 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
CN113698391A (zh) * | 2020-05-21 | 2021-11-26 | 上海拓界生物医药科技有限公司 | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 |
WO2022166799A1 (zh) * | 2021-02-03 | 2022-08-11 | 上海拓界生物医药科技有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
Also Published As
Publication number | Publication date |
---|---|
TW202406912A (zh) | 2024-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11629153B2 (en) | Forms and compositions of a MK2 inhibitor | |
WO2018170204A1 (en) | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof | |
WO2021023194A1 (zh) | 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 | |
WO2011163430A1 (en) | Polymorphs of osi-906 | |
EP3947375B1 (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
TW202241902A (zh) | 一種嘧啶并五元氮雜環類衍生物的晶型及其製備方法 | |
WO2022166799A1 (zh) | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 | |
CN113698391B (zh) | 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法 | |
WO2021023192A1 (zh) | 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法 | |
WO2024027631A1 (zh) | 一种稠三环类衍生物的晶型及制备方法 | |
CN114728973A (zh) | 一种核蛋白抑制剂的晶型及其应用 | |
WO2022068860A1 (zh) | 一种吡咯并杂环类衍生物的晶型及其制备方法 | |
WO2020164603A1 (zh) | 固体形式的fgfr抑制剂化合物及其制备方法 | |
WO2019085893A1 (zh) | 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法 | |
CN117486898A (zh) | 一种稠三环类衍生物的晶型及制备方法 | |
WO2021164789A1 (zh) | 一种吡唑并嘧啶类化合物的晶型及其应用 | |
WO2023151660A1 (zh) | 一种p2x3受体拮抗剂的结晶形式及其制备方法 | |
WO2023174300A1 (zh) | Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型 | |
WO2020221358A1 (zh) | Wee1抑制剂化合物的晶型及其应用 | |
RU2787767C2 (ru) | Кристалл производного бензоксазола | |
WO2023125947A1 (zh) | 四氢异喹啉类化合物的可药用盐、晶型及其用途 | |
WO2019242646A1 (zh) | 催产素受体抑制剂的晶型及其制备方法 | |
CN115232124A (zh) | 一种atx抑制剂的结晶形式及其制备方法 | |
CN116836149A (zh) | 吡嗪硫联苯基类化合物的晶型及其应用 | |
TW202408510A (zh) | Cdk抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23849339 Country of ref document: EP Kind code of ref document: A1 |